Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 678 across all filing types
Latest filing 2023-08-31 Board/Management Inform…
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Change in Auditors
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the appointment of new statutory auditors following the conclusion of the Annual General Meeting (AGM). It references the approval of the appointment at the 45th AGM and provides details about the new auditors, including their term and profile. The document does not contain financial statements or audit results but is an announcement of a change in auditors. This fits the category of Board/Management Information (MANG), as it relates to changes in key company officers (statutory auditors). The document length is short (2541 characters), and it is not a report or certification but an official announcement. Therefore, the correct classification is MANG with high confidence.
2023-08-31 English
Shareholders meeting
Regulatory Filings
2023-08-31 English
Updates
Regulatory Filings Classification · 95% confidence The document is a notification letter addressed to stock exchanges about a US FDA inspection at the company's manufacturing facility. It reports observations received on Form 483 and the company's commitment to respond. The document is short (1697 characters) and serves as an announcement of regulatory inspection results rather than a detailed report or financial filing. It does not contain financial data, management changes, or voting results. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2023-08-26 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding a newspaper advertisement pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It mentions the publication of advertisements to inform shareholders, which is a regulatory compliance announcement rather than a financial report or detailed filing. The document length is short (1616 characters) and it does not contain financial data, management discussion, or detailed report content. It is an announcement for regulatory compliance purposes, fitting best under Regulatory Filings (RNS).
2023-08-26 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is an addendum to the notice of the 45th Annual General Meeting (AGM) of Gland Pharma Limited. It specifically addresses an update to the details of the statutory auditors to be appointed, including remuneration details. The document is dated August 25, 2023, and references the original AGM notice dated August 1, 2023. The content is an official communication to shareholders and stock exchanges about an addendum to the AGM notice, not the AGM materials themselves or the AGM meeting minutes. The document length is 4290 characters, which is relatively short and consistent with an announcement or notice rather than a full report. Therefore, this document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or AGM Information (AGM-R). However, since it is an addendum to the AGM notice and not the AGM presentation or materials, it is more appropriate to classify it as AGM Information (AGM-R), which includes presentations and materials shared during the AGM process, including notices and addenda to notices.
2023-08-25 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short letter dated August 24, 2023, addressed to stock exchanges, informing about the conclusion of a US FDA inspection at the company's manufacturing facility. It references a previous letter dated July 14, 2023, and states that the Establishment Inspection Report (EIR) has been received indicating closure of the inspection. The document is brief (1371 characters) and serves as an announcement of an event related to regulatory compliance rather than a detailed report or financial filing. There is no financial data, no management discussion, no voting results, no audit information, or other report content. It is a regulatory announcement informing the market about the inspection outcome. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-08-24 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.